1.Treatment of primary central nervous system lymphoma
Journal of International Oncology 2016;43(1):71-74
As a kind of rare central nervous system malignant tumor, primary central nervous system lymphoma (PCNSL) has poor prognosis, and the main treatment include surgery, radiotherapy and chemotherapy.Stereotactic biopsy has become a routine diagnostic method of PCNSL, because of which has the advantage of minimally invasive and convenient.Whole brain radiotherapy is a standardized treatment method for the multifocal PCNSL, which can delay the progress of tumor in a short term.The therapeutic regimen based on high dose methotrexate leads to significant changes in the PCNSL treatment and it has become an effective treatment measure.Effective comprehensive treatment is the key to extending survival time and improving the quality of life for the patients with PCNSL.
2.Study on the clinical efficacy of paclitaxel and capecitabine in treatment ofⅣ period lung adenocarcinoma
Chinese Journal of Biochemical Pharmaceutics 2014;37(4):131-133
Objective To explore the clinical efficacy of paclitaxel(taxol,TAX)and capecitabine scheme(capecitabine,CAPE)in treatment ofⅣperiod lung adenocarcinoma.Methods 90 patients with Ⅳ period lung adenocarcinoma from March 2011 to August 2013 were collected and randomly divided into two groups,control group(n =45 )were given CAPE treatment and experimental group (n =45 )were given CAPE +TAX combination therapy.After treatment,the clinical efficacy and side effects in two groups were observed and compared. Results Evaluation of recent efficacy:the efficacy(response rate,RR)of experimental group was 46.67%,the disease control rates(DCR)was 77.78%,while RR of control group was 48.89%and DCR was 73.33%,there was no statistical significance between two groups.Evaluation of long-term efficacy:progression-free survival (PFS )in experimental group was(6.18 ±3.12)months,while in control group was(3.09 ±2.29)months,the difference was statistically significant(P<0.05). Overall survival(OS)in experimental group was(9.19 ±2.04)months,while in control group was(8.63 ±3.93)months,there was no statistical significance between two groups.Evaluation of adverse reaction:in terms of hematology change,white blood cell count(WBC),neutrophil counts(NE)in experimental group were decreased significantly than control group,the difference were statistically significant(P<0.05 ),but not the PLT.In terms of the hematology change,alopecia in experimental group was more than in control group,the difference was statistically significant(P<0.05 ),but there were no changes in nausea and vomiting,the brotherhood of syndrome,liver damage,oral cavity mucous membrane inflammation.Conclusion CAPE and TAX has good clinical efficacy in treatment of stage Ⅳ lung adenocarcinoma.It can increase the progression-free surial,and side effects is in hematology change.
3.Diagnosis and treatment of primary central nervous system lymphoma
Journal of International Oncology 2013;40(8):621-624
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma (NHL) and has aggressive biological behavior.Due to absence of typical clinical presentation,heterogeneity of pathological morphology and multiple neuroimaging appearance and so on,the immunohistochemistry and molecular biology are of vital importance in accurate diagnosis of PCNSL.The development of regimen based on high-dose MTX leads to significant changes in the PCNSL treatment and it has become a generally recognized regimen.Compared with single radiotherapy,the survival rate has evidently been raised.Early diagnosis and surgical removal of the tumors combined with effective radiotherapy and chemotherapy are the key to extending survival period and improving living quality of patients with PCNSL.
4.Reversal for acquired resistance to EGFR inhibitors in lung cancer
Journal of International Oncology 2013;40(11):843-846
Epidermal growth factor receptor (EGFR) inhibitors targeted therapy is the forward position means for non-small cell lung cancer.However,acquired resistance to EGFR inhibitors limits the development of targeted drugs.Using existing data on drug resistance in EGFR-mutant lung cancer,this review discusses three basic approaches for overcoming resistance to EGFR-targeted therapies:intensification of EGFR inhibition,combination of EGFR inhibitors with other targeted therapies,and altering clinical management via alternate pathways.
5.Advances of long non-coding RNA UCA1 in cancers
Dali YAN ; Haixia CAO ; Jifeng FENG
Journal of International Oncology 2017;44(2):108-111
Long non-coding RNA urothelial carcinoma associated 1 (UCA1) is initially discovered and named in bladder cancer tissue,which is highly expressed in multi types of tumor tissues,such as bladder cancer,ovarian cancer,lung cancer,suggesting that UCA1 acts as oncogene.UCA1 is confirmed to regulate tumor cell proliferation,apoptosis,invasion and migration,which plays an important role in the occurrence and development of cancers.UCA1 is expected to become a new biomarker for diagnosis,prognosis and drug susceptibility,which may be a promising therapeutic target of cancer.
6.Mechanism and strategy of the secondary resistance to EGFR-TKI in patients with lung cancer
Siwen LIU ; Shaorong YU ; Jifeng FENG
Journal of International Oncology 2015;42(1):56-59
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is one of the most important targeted drugs for lung cancer patients carrying EGFR sensitive mutations.However,almost all patients that are effective to this treatment will eventually develop secondary resistance to EGFR-TKI.The most accepted mechanisms of resistance mainly include T790M mutation,MET amplification,PIK3CA mutation,down-regulation of PTEN expression and activation of Fas-transcription factor-κB.Recent years,many new drugs are developed to overcome this resistance.Although most of drugs are in the stages of cell or animal experiment,some new drugs get positive clinical results.
7.Research progression on resistance mechanisms of epidermal growth factor receptor tyrosine kinase ;inhibitors in non-small cell lung cancer
Yun LIU ; Jifeng FENG ; Zhaoyue YAN
Journal of International Oncology 2015;(3):206-209
EGFR-TKI plays an important role in the treatment of non-small-cell lung cancer. However, some researchers find that there are still some patients with primary or acquired resistance to EGFR-TKI. The present known mechanisms of acquired drug resistance finally lead to the re-activation EGFR downstream signa-ling pathways. Liver X receptor agonist has inhibition function to several critical steps of EGFR downstream sig-naling pathways PI3K-Akt-NF-κB,which makes it possible to overcome the drug resistance.
8.Transfection of human endostatin gene in umbilical cord CD34~+ hematopoietic stem cell
Jifeng FENG ; Liangjun ZHU ; Ji HU
Journal of Medical Postgraduates 2004;0(02):-
Objective:To transfer human endostatin gene into umbilical cord CD34 + hematopoietic stem cells and detect its expression and excretion. Methods: Human endostatin gene was transferred into human umbilical cord CD34 + hematopoietic stem cells by retroviral pLNCX to build endostatin-transferred cell line.RT-PCR and Western blot analysis were applied to examine the transfection and expression of endostatin gene. Results:RT-PCR proved that genome of endostatin-transferred CD34 + hematopoietic stem cells contained a 550 bp fragment of human endostatin .The expression and excretion of human endostatin from endstatin-transferred hematopoietic stem cells were confirmed by Western blot analysis. Conclusion:Human endostatin gene can be transferred into CD34 + hematopoietic stem cells.
9.Studies on a selective cyclooxygenase-2 inhibitor celecoxib inhibiting growth of human hepatocellular cancer SMMC-7721 cells lines and inducing apoptosis
Guohao XIA ; Hong CHEN ; Zhi WANG ; Liangxi PAN ; Jifeng FENG
China Oncology 2006;0(09):-
Background and purpose:The incidence of hepatoma is high. The outcome of treatment on hepatoma is poor.So we investigated the effect and mechanism of a selective cyclooxygenase-2 inhibitor celecoxib on the proliferation and apoptosis of SMMC-7721 hepatoma cell line. Methods:MTT assay was used to study the inhibitive effect of celecoxib on the growth of SMMC-7721 hepatoma cell. The effect of celecoxib on cell cycle and apoptosis on cells was studied by flow cytometry(FCM).Transmission electron microscopy (TEM) was used to display the morphological change of the SMMC-7721 hepatoma cell . The biochemical character of apoptosis was viewed on the agarose gel electrophoresis.The expression of bax gene and bcl-2 gene were measured by immunohistochemistry.Results:The SMMC-7721 cells were cultured in media that contained 25,50,75,100 ?mol/L celecoxib,by means of MTT, the inhibition rate was(15?3)%,(34.6?2.4)%,56.8?1.0)%,(86.2?0.4)% respectively after 24 hours; but the inhibition rate was (33.4?0.7)%,(66.7?1.8)%,(76.1?2.4)%,(97.3?0.8)% respectively after 48 hours(P
10.Exogenous EGF Effect on Change of Ultra-structure in Sensory Neuron Following Nerve Injury in Rat
Feng ZHANG ; Yudong GU ; Jianguang XU ; Jifeng LI
Fudan University Journal of Medical Sciences 2000;27(6):446-448,452
Purpose To observe exogenous epidermal growth factor (EGF) influence upon sensory neurons axotomy-induced and change ultra-structure of sensory. Methods Eighteen male Sprague-Dawely rats weighing 180-200 g(8-9 weeks of age)were randomly divided into two groups.One as control,the other was treated with EGF.Sciatic nerve injury model was set up by transecting left side sciatic nerve at 0.5 cm away from performed muscle.The proximal stump of sciatic nerve was ligated to inhibit nerve regeneration.Then 5 μl of normal saline in the control groups and an equal volume of EGF solution (containing 10 μg EGF) in the EGF treated groups were injected into the proximal of ligated nerve.The rats were sacrificed in 7,14,28 days of operative intervals respectively and transcardialy perfused with 4% para-fromaladehyde.The L5 dorsal root ganglion(DRG) were harvested.Eletromicroscope technique was used to observe the changes of L5 DRG sensory neurons axotomy-induced. Results A series of changes happened in the control group.The size of the nucles decreased.Nucleoplasm was scattered.The nucleolus was pale.Edema,loss of crest and matrix was found in the mitochondria. Satellite cells detached from the soma.The ultrastructure of L5 DRG sensory neurons in EGF groups get near to normal following nerve injury. Conclusions EGF could protect sensory neurons.